KROS

Keros Therapeutics Stock Analysis

AI Rating

Great
  • Quality9/10
  • Growth↑ 9/10
  • Momentum↑ 5/10
Keros Therapeutics sales and earnings growth
KROS Growth
Great
  • Revenue Y/Y↑ 37798.31%
  • EPS Y/Y↑ 130.71%
  • FCF Y/Y↑ 161.11%
Keros Therapeutics gross and profit margin trends
KROS Profitability
Great
  • Gross margin ↑ 100.00%
  • EPS margin↑ 26.10%
  • ROIC↑ 160.40%
Keros Therapeutics net debt vs free cash flow
KROS Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Keros Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗